LabGenius Therapeutics has announced the initiation of a second research collaboration with Sanofi aimed at advancing the design and optimisation of therapeutic NANOBODY® molecules for inflammatory disease targets. The partnership builds on outcomes from an earlier program and leverages LabGenius’ machine learning–driven experimental platform alongside Sanofi’s expertise in therapeutic Nanobody development.
Under the new agreement, LabGenius will apply its proprietary EVA™ platform, an integrated system combining artificial intelligence, robotic laboratory automation, and high-throughput synthetic biology, to guide iterative cycles of antibody design, synthesis, and functional screening. The objective of the collaboration is the systematic co-optimization of protein sequences across multiple performance parameters relevant to therapeutic development, including affinity, stability, and developability. The program will address several novel inflammatory targets designated by Sanofi.
We are truly excited about this new collaboration with Sanofi. This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients.
Dr. Angus Sinclair, CSO, LabGenius
The EVA™ platform is designed to close the experimental feedback loop between computational prediction and empirical validation. Machine learning models propose candidate variants, which are produced and functionally assayed at scale, resulting datasets are then used to retrain subsequent predictive models. This approach seeks to accelerate exploration of protein fitness landscapes relative to conventional antibody engineering workflows.
LabGenius operates a hybrid business model that includes partnered discovery programs alongside internal development of wholly owned therapeutic assets. The company focuses on applying data-driven methodologies to enable next-generation antibody design and optimisation.